Clinical Trial Update: Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating a 2-week Docetaxel regimen for HER2-negative metastatic breast cancer. The sponsor is Zhejiang C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN